James H L, Girolami A, Hubbard J G, Kumar A, Fair D S
Department of Biochemistry, University of Texas Health Center, Tyler 75710.
Biochim Biophys Acta. 1993 Mar 20;1172(3):301-5. doi: 10.1016/0167-4781(93)90217-2.
This study addresses whether a mutation in the factor VIIPadua gene could explain the reduced activity of the inherited variant protein. All nine exons of the normal and Padua factor VII gene were amplified using the polymerase chain reaction, cloned into pUC19 and sequenced. A point mutation (G to A at nucleotide position 10828) was found which results in the substitution of a glutamine (CAG) for arginine (CGG) at amino acid position 304. This substitution creates a PvuII restriction site useful in screening for the defect and in demonstrating homozygosity. This substitution involves an arginine residue in the catalytic domain within a LeuPro*Cys motif which occurs in conserved region 5 in up to 16 coagulation and other serine proteinases. On the basis of conformational homology among serine proteinases, it is suggested that the observed amino acid substitution in factor VIIPadua could cause structural changes affecting its activation and/or catalytic activity.
本研究探讨了凝血因子VII帕多瓦基因的突变是否能够解释遗传性变异蛋白活性降低的现象。采用聚合酶链反应扩增正常和帕多瓦凝血因子VII基因的全部9个外显子,克隆至pUC19载体并进行测序。发现了一个点突变(核苷酸位置10828处的G突变为A),该突变导致第304位氨基酸处的谷氨酰胺(CAG)被精氨酸(CGG)取代。这种取代产生了一个PvuII限制性酶切位点,可用于筛选该缺陷并证明纯合性。这种取代涉及到位于LeuPro*Cys基序内催化结构域中的一个精氨酸残基,该基序存在于多达16种凝血及其他丝氨酸蛋白酶的保守区域5中。基于丝氨酸蛋白酶之间的构象同源性,提示凝血因子VII帕多瓦中观察到的氨基酸取代可能导致结构变化,从而影响其激活和/或催化活性。